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The Ets2 transcription factor is regulated by mitogen-activated protein (MAP) kinase phosphorylation of a
single threonine residue. We generated by gene targeting a single codon mutation in Ets2 substituting Ala for
the critical Thr-72 phosphorylation site (Ets2
A72), to investigate the importance of MAP kinase activation of
Ets2 in embryo and tumor development. Ets2
A72/A72 mice are viable and develop normally. However, combining
the Ets2
A72 allele with a deletion mutant of Ets2 results in lethality at E11.5 and shows that Ets2
A72 is a
hypomorphic allele. Mammary tumors caused by transgenic polyomavirus middle T antigen, activated Neu
(Erbb2), or the combination of Neu and transgenic VEGF (Neu; VEGF-25) were all restricted in Ets2
A72/A72
females. The Ets2
A72/A72 restriction on Neu; VEGF-25 tumor growth was associated with increased p21
Cip1
expression. The size of tumors transplanted into fat pads of mice with Ets2 targeted alleles was correlated
directly with Ets2 activity and fewer stromal cells expressing matrix metalloproteinase 9 (MMP-9). Decreased
MMP-3 and MMP-9 mRNAs were conﬁrmed in Ets2
A72/A72 macrophages. Activation of Ets2 at Thr-72 acts in
the stroma, downstream of vascular endothelial growth factor production, in part through the regulation of
macrophage proteases to support the progression of Neu- and polyomavirus middle-T-initiated mammary
tumors.
Most cancers are epithelial in origin. However, a signiﬁcant
and sometimes predominate portion of breast, colon, stomach,
and pancreas tumors are host ﬁbroblasts, endothelial cells,
inﬂammatory cells, smooth muscle cells, adipocytes, and extra-
cellular matrix known collectively as stroma (6). Much less is
known about the molecular genetics of tumor-stroma interac-
tion than is known about epithelial transformation. Tissue
stroma can both suppress and promote tumor progression (16,
57). Among the examples of stroma-neoplasia communication
is the role of matrix metalloproteinases produced by ﬁbroblasts
and invasive inﬂammatory cells in the angiogenic switch asso-
ciated with pancreatic and skin neoplastic progression (5, 10).
Ets2 is one of over 25 transcription factors in the human
genome that utilize the Ets winged helix-loop-helix DNA-bind-
ing domain (30, 54). Extracellular signal-regulated kinase 2
(Erk2) binds to Ets2 through a docking site in the evolution-
arily conserved, N-terminal pointed domain of a subset of Ets
transcription factors (44). The signal transduction pathway
from growth factor receptors, such as ﬁbroblast growth factor
(FGF) receptor and epidermal growth factor receptor (EGFR;
Erbb1), through the Ras–mitogen-activated protein kinase
pathway to the pointed domain of Ets transcription factors is
used for regulating developmental transitions in Drosophila
melanogaster and Caenorhabditis elegans and growth factor sig-
naling in humans and mice. In Drosophila the closest relative of
Ets2, the Pointed-P2 product of the pointed gene, is key in
Ras-pathway-dependent photoreceptor development (40) and
in tracheal ductal morphogenesis (42). In mammals, Ets2 has
been implicated in growth factor stimulation of macrophages
(7, 31, 45, 49); FGF stimulation (59); and oncogenic stimula-
tion by Neu (23), Ras (60), and Raf (36). The expression of
either wild-type Ets2 or a dominant-negative form of Ets2 can
reverse the transformed characteristics of human or mouse
cancer cell lines (17, 18). Inactivation of Ets2 by a gene-tar-
geted deletion of the DNA-binding domain and nuclear local-
ization signal (Ets2
db1) results in embryonic lethality associated
with deﬁcient expression of matrix metalloproteinase 9
(MMP-9) and CD31 in trophoblastic derivatives (59). Haplo-
insufﬁciency of Ets2 is sufﬁcient to restrict mammary tumors
arising from polyomavirus middle T (PyMT) oncogene expres-
sion driven by the mouse mammary tumor virus (MMTV) long
terminal repeat promoter (38).
Here, we show that mutation of Thr-72 creates a hypomor-
phic allele of Ets2 (Ets2
A72), which acts, at least in part, in host
stroma to restrict mammary tumors. This tumor restriction is
genetically downstream of vascular endothelial growth factor
(VEGF) production and is correlated with decreased macro-
phage MMP-3 and MMP-9 expression.
MATERIALS AND METHODS
Gene targeting. The Ets2
A72 targeting vector was prepared from a 14.4-kb Ets2
genomic clone containing exons 3 to 9 (26). The codon for Thr-72 and a PstI
restriction site encoded by codons 73 and 74 were changed using synthetic
oligonucleotides and PCR of a 662-bp HindIII fragment spanning exon 4. A
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inserted into an FspI site in intron 4, and a thymidine kinase gene was added to
the 3 end of the vector to utilize ganciclovir selection (35). The ﬁnal vector
contained the Neo gene ﬂanked by 2 and 4 kb of Ets2 genomic sequence. DNA
was introduced into embryonic stem (ES) cells by electroporation, and G418-
and ganciclovir-resistant colonies were isolated by the Burnham Institute Mouse
Molecular Genetics service. Two targeted ES cell clones were identiﬁed from 86
clones screened by PCR with one primer 5 of targeting vector sequences (TT
TGCTGTGCTCCCTTCTCTCAGT) and a primer, MA-AM11B-loxPneo (AA
GAACGAGATCAGCAGCCTCTGT), within the vector, resulting in a 2.28-kb
product. One clone was conﬁrmed by Southern blot analysis with probes ﬂanking
the targeting vector. This allele was designated Ets2
A72-Neo.
Chimeric animals were generated by the injection of Ets2
A72-Neo/ ES cells into
C57/BL6 blastocysts by standard methods (28). Subsequent progeny were
screened by PCR of DNA isolated from tail biopsy samples with the primer
cDNA5BR (CTCTGCAGACTGGGGCTTATTC) and the MA-AM11B-lox-
Pneo primer, generating a 506-bp product. The Neo gene was excised by mating
Ets2
A72-Neo/ mice with pCXxNLS-Cre15, Cre-expressing deletion mice, kindly
provided by Steve O’Gorman (Salk Institute, La Jolla, Calif.) (39). Mice positive
for Cre-mediated excision were screened by PCR with the primers cDNA5BR
and MA-AM11-4165 (GCAGGGAGAGCAAGAAAGGACAC), giving a
506-bp product for wild-type Ets2 and a 607-bp product for Ets2
A72. To screen for
the PyMT transgene, the primers MT-665 (CCAACCCGAGATGTGCTGAA)
and MT-1310 (CTGCAAATCCCGAAGAATCA) were used for PCR of tail
DNA for both the MMTV-PyMT (Jackson Laboratory; FVB/N-TgN
[MMTVPyVT] 634 Mul) and MMTV-PyVMT
Y315,322FDb-4 (MMTV-PyMT)
(56) lines. The MMTV-VEGF-25 (VEGF-25) transgenic mouse line expresses
the mouse VEGF164 form of VEGF in mammary epithelium (40a). The trans-
gene was screened by tail PCR with primers GAAAGACCGATTAACCATG
TCAC and TCAGCAGTAGCCTCATCATCA.
Tumor transplantation. The MMTV-PyMT
Y315,322F-DB7 serially trans-
planted mouse mammary tumor line was established and carried in the FVB/N
mouse strain by serial transplantation of a tumor arising due to the MMTV-
driven expression of PyMT antigen containing point mutations of the codons for
tyrosines 315 and 322 (8, 56). Adult female mice heterozygous for the Ets2
db1
targeted allele (59) on an FVB/N genetic background or wild-type littermates of
78- to 114-day-old mice were used as recipients. Ets2
A72/ or Ets2
A72/A72 litter-
mates bred ﬁve or more generations into the FVB/N background were also used
as hosts. Pieces of PyMT
Y315,322F-DB7 tumors 1 mm
3 in volume were surgically
inserted into both no. 4 mammary fat pads of each recipient as described
previously (8, 61). The genotypes of the recipients were not known to the surgeon
at the time of implantation. After 8 to 9 days (experiment 1) and after 9 days
(experiments 2 and 3) animals were sacriﬁced and the fat pads were removed,
mounted on glass slides, ﬁxed in acidic ethanol or Carnoy’s ﬁxative, stained with
carmine alum, dehydrated through ethanol and toluene, and mounted in Per-
mount. Tumors were photographed with an Olympus Z40 dissection microscope
and a Nikon Coolpix 990 digital camera. Tumor size was measured with the use
of NIH Image software by identifying the border of the tumors as a gray-scale
threshold and converting the area in pixels to square millimeters by reference to
a standard grid. The area was converted to volume by assuming a sphere with
cross-sectional area equal to the measured value. After photography, the tissue
was removed from the slide and embedded in parafﬁn, and 10-m sections were
stained with hematoxylin and eosin. Lymph nodes were measured by the same
method as a control and reference.
The same incisions used for the mammary gland clearing technique were made
for the subcutaneous transplantation of PyMT
Y315,322F tumor segments 1 mm
3 in
size. The skin was folded back, and the ﬁrst bifurcation of the blood vessel
anterior to the inguinal lymph node in the no. 4 fat pad was located. A tiny
pocket was made in the connective tissue fascia, and the tumor tissue was placed
between the bifurcation of the vein, beneath the connective tissue layer and the
dermis. After 9 days, the tumors were dissected attached to the skin. The skin
was mounted on cork and ﬁxed in 4% paraformaldehyde in phosphate-buffered
saline (PBS). Tumor size was assessed by image analysis of digital images ac-
quired after brief carmine staining and using incident light.
BMMs. Bone marrow-derived macrophages (BMMs) were prepared by iso-
lating bone marrow from the femurs of 7- to 10-week-old female mice. Bone
marrow was cultured in Dulbecco’s modiﬁed Eagle’s medium containing 10%
fetal bovine serum–20 ng of colony-stimulating factor 1 (CSF-1) (Chemicon)/ml
for 7 days and then dispersed to 500,000 cells per well in six-well trays. BMMs
undergoing CSF-1 stimulation were cultured without CSF-1 for 16 h and then
treated with 20 ng of CSF-1/ml for 8 h. BMMs undergoing lipopolysaccharide
(LPS)-gamma interferon (IFN-) treatment were cultivated with 20 ng of CSF-
1/ml for 16 h and then stimulated with an additional 100 ng of LPS/ml and 100
U of IFN-/ml for 8 h.
Immunohistochemical detection of MMP-9, F4/80, and factor VIII. Sections (5
m) were deparafﬁnized, hydrated to PBS, incubated in 5% H2O2 in PBS for 5
min, digested with Ficin (Zymed, South San Francisco, Calif.) for 10 min, and
blocked for 30 min with 5% normal goat serum (DAKO, Glostrup, Denmark)
and 3% bovine serum albumin (BSA) in PBS and with the avidin-biotin blocking
kit (Vector Laboratories, Burlingame, Calif.) according to the manufacturer’s
instructions. Sections were incubated overnight at 4°C with polyclonal rabbit
anti-MMP-9 (3) diluted 1:500 in 0.1% BSA-PBS, washed, and incubated for 1 h
at room temperature with biotin-conjugated goat anti-rabbit antibody (DAKO)
diluted 1:250 in PBS-BSA. After extensive washing with 0.1% BSA-PBS, the
sections were incubated with streptavidin-horseradish peroxidase conjugate
(Amersham Biosciences, Piscataway, N.J.) diluted 1:100 in 0.1% BSA-PBS and
developed by incubating the slides with diaminobenzidine (Zymed) for 10 min.
Sections were brieﬂy counterstained with hematoxylin before mounting. The
numbers of MMP-9-positive cells in the tumors and the tumor-stromal interface
were counted, and the size of the counted area was determined using Image
software from the National Institutes of Health (NIH).
F4/80 rat monoclonal antibody (Caltag) diluted 1/60 and rabbit anti-factor
VIII-related antigen (DAKO A0082) diluted 1/1,000 were used on Carnoy’s
ﬁxative-ﬁxed, parafﬁn-sectioned material. Mouse-absorbed, biotinylated anti-rat
secondary antibody (Vector Laboratories) was used at 5 g/ml. The ABC Delux
system (Vector Laboratories) and diaminobenzidine development were used for
detection. Rabbit antibody was detected with the DAKO EnVision peroxidase-
conjugated dextran complex and diaminobenzidine development. F4/80 staining
of transplanted tumor sections was measured by converting digital images to gray
scale and then black and white with the use of the threshold command. The total
area of staining was measured with the use of NIH Image software.
Digital images of Fig. 2C and D and Fig. 6C to F were captured at 1,026 by
2,060 pixels using an AxioCam digital camera (Zeiss) mounted on a Zeiss
microscope. The images were processed using PhotoShop software. Scale bars
were inserted before reduction.
RNA analysis. RNA was prepared with the use of Trizol reagent (Invitrogen)
(9). The cDNA was prepared from 1 g of total RNA using oligo(dT) priming
and Superscript II reverse transcriptase (Invitrogen). The cDNA levels were
quantiﬁed by real-time PCR in a LightCycler instrument using the SYBR Green
I PCR kit and the LightCycler software (Roche Diagnostics GmbH). Gene
expression was normalized to the level of cyclophilin A (Cph) in the same cDNA
sample, and a standard curve generated with Cph primers was used to estimate
relative differences in gene expression (27). The two primers for each target were
as follows: Cph/(Ppia), AGACCAGCAAGAAGATCACC and GGAAAATAT
GGAACCCAAAG; Bcl-xL/(Bcl2l set 1), GACGTGATCATTTCCCATC and
GAGGTTCTGGTCCTTGTCTC; Bcl-xL/(Bcl2l set 2), TCAGAGCTTTGAGC
AGGTAG and AAGGCTCTAGGTGGTCATTC; CycD1/(Ccnd1), AGGTAA
TTTGCACACCTCTG and ACAAAGCAATGAGAATCTGG; VEGFa/(Vegfa,
3 noncoding), GAAGAAGAGGCCTGGTAATG and GGAAGATGAGGAA
GGGTAAG; VEGF/(Vegfa, coding), CAGGCTGCACCCACGACAGAAG
and CTATGTGCTGGCTTTGGTGAGGTTT; p21/(Cdkn1a), GGGTTCTCAG
TGACTTCTCC and CCACTAAGTGCTTTGACACC; MMP-3, TTAAAGAC
AGGCACTTTTGG and CAGGGTGTGAATGCTTTTAG; MMP-9, CGTCT
GAGAATTGAATCAGC, and AGTAGGGGCAACTGAATACC; Ets2, CAG
AGGCCTAATCCTCAGTC and GGCCAAATTACAAAACCTTC.
Ets2 protein analysis. Mouse embryo ﬁbroblasts were isolated from 12.5-day
Ets2
A72/A72 and Ets2
/ embryos by standard methods (28). Exponentially grow-
ing cultures were labeled with 500 Ci of [
35S]methionine (Amersham)/ml for 20
min. Cells were harvested either immediately or after incubation in normal
complete medium for up to1ha sindicated. Cells were lysed, and proteins were
immunoprecipitated with rabbit anti-Ets2 antiserum and analyzed by acrylamide
gel electrophoresis and autoradiography as previously described (28). Fourteen-
day ﬁlm exposures were processed with NIH Image software to measure image
intensity.
RESULTS
Generation of an Ets2
A72 knock-in allele. In cultured cells
Ets2 basal transcriptional activity is activated by the phosphor-
ylation of threonine-72 by oncogenes or growth factors that
utilize the Ras–mitogen-activated protein kinase pathways
(60). We introduced a single nucleotide change in codon 72 of
mouse Ets2 to change it from Thr to Ala (Ets2
A72). In addition,
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troduced to eliminate a diagnostic PstI restriction site (Fig.
1A). The targeting vector containing the mutations and a Neo
gene ﬂanked by LoxP recombination sites was introduced into
the Ets2 gene of ES cells. Two correctly targeted ES clones
were identiﬁed. Southern blot analysis conﬁrmed the expected
structure of the targeted gene (Fig. 1B). PCR, restriction en-
zyme digestion (Fig. 1C), and DNA sequencing of ampliﬁed
genomic DNA (data not shown) conﬁrmed the presence of the
two mutant nucleotides. Upon identiﬁcation and germ line
transmission of the targeted Ets2
A72-Neo allele, the Neo select-
able gene was removed by mating to mice expressing Cre
recombinase from the protamine promoter in the male germ
line (39) (Fig. 1D). This created the Ets2
A72 allele. Ets2
A72
RNA was found to be expressed at the same levels as that of
wild-type Ets2 (see below). This indicates that the LoxP se-
quence left in intron 4 in the Ets2
A72 allele does not interfere
with the expression of the gene at the RNA level. To determine
if A72 alteration might alter the degradation of the Ets2
A72
protein, the turnover of Ets2 was determined in mouse embryo
ﬁbroblasts derived from Ets2
A72/A72 and wild-type embryos.
Cells were labeled with [
35S]methionine for 20 min and then
incubated in medium with normal levels of nonradioactive
methionine for various times up to 60 min. Ets2 was immuno-
precipitated and detected by enhanced autoradiography of a
gel used to separate the immunoprecipitated proteins (Fig.
1E). Ets2 was identiﬁed by reference to a sample from 3T3
cells, which were transfected with an Ets2 expression vector
and then labeled with radioactive methionine (Fig. 1E, lanes 9
and 10). Newly synthesized Ets2 protein was degraded rapidly
with an estimated half-life of 10 min (Fig. 1F). The newly
synthesized Ets2
A72 protein was found at comparable levels
and turned over similarly in comparison to wild-type Ets2. This
result indicates that the effects of the A72 mutation are not due
to increased turnover of the mutant protein. It also conﬁrms
the very rapid turnover of Ets2 (20).
Developmental haploinsufﬁciency of Ets2
A72. The previously
described Ets2
db1 allele represents a deletion of the DNA-
binding domain and nuclear localization signal. In a homozy-
gous state Ets2
db1 does not support embryonic development
(59). After ﬁve generations of breeding into the FVB/N genetic
background, Ets2
A72/ heterozygotes were inbred to determine
viability. Ets2
A72/A72 homozygous progeny were found at ex-
pected Mendelian ratios (data not shown). Thus, two Ets2
A72
alleles are sufﬁcient to prevent extraembryonic tissue deﬁ-
ciency. However, when Ets2
A72/A72 mice were bred with
Ets2
db1/ heterozygotes, only Ets
A72/ progeny were recovered
(Table 1). Thus, while two Ets
A72 alleles are permissive, de-
creasing Ets2 by an additional 50% is not tolerated. Ets2
db1/db1
embryos die at about 8.5 days of development (59). Analysis of
embryos derived from Ets2
A72/A72 and Ets2
db1/ parents re-
vealed that Ets2
A72/db1 embryos survived until about E11.5
(Fig. 2B). E10.5 embryos were signiﬁcantly smaller and re-
tarded in their development (Fig. 2A). Furthermore, the yolk
sacs of Ets2
A72/db1 embryos failed to develop blood vessels
although blood could be seen within the embryos proper (Fig.
2A). The abnormal development of Ets2
A72/A72 embryos was
associated with smaller, disorganized placentas lacking a lab-
yrinth region where maternal and embryonic vascular systems
intermingle (Fig. 2C and D). Ets2
A72/db1 embryos survived ap-
FIG. 1. Construction of the Ets2
A72 allele. (A) The two nucleotides
of the mutant allele are highlighted in the top strand, and the wild-type
sequence is highlighted in the lower strand. The second mutation
abolishes the PstI site. Maps of the relevant portion of Ets2 are shown
with larger blocks and numbers indicating exons and a white block
indicating exon 4 containing the Ets2
A72 mutations. LoxP recombina-
tion sites and orientations are shown as triangles. Recombination of
the targeting vector with the Ets2 gene generates the Ets2
A72-Neo allele.
Mating of mice carrying the Ets2
A72-Neo allele with a transgenic mouse,
which expresses Cre in the male germ line, results in excision of the
Neo gene, leaving one LoxP element. H, HindIII; pA, pB, and pC,
PCR primer sites; Tk, thymidine kinase gene used for negative selec-
tion in ganciclovir; Neo, phosphoglycerate kinase-Neo gene providing
resistance to the drug G418. (B) Southern blot of targeted ES clones.
DNA was digested by HindIII. The 6.2-kb wild-type band and the
8.2-kb A72-Neo band were detected by probe A, shown in panel A.
Lanes 1, 2, and 4 represent wild-type ES cell clones. Lane 3 is
Ets2
A72-Neo/ clone 135. Numbers at left are molecular sizes in kilo-
bases. (C) PCR analysis of ES cells. DNA samples: 1, cloned Ets2
/
gene fragment; 2, Ets2
/ genomic DNA; 3, Ets2
A72-Neo/ clone 135; v,
targeting vector DNA. Ampliﬁcation with primers pA and pB or pA
and pC is indicated. Samples in lanes 7 to 10 were digested with PstI.
Both the A72-Neo targeting vector and clone 135 contain the mutation
eliminating the PstI site. (D) PCR products of progeny of breeding
Ets2
A72-Neo/ and Cre deletion mice using primers A and B. The wild-
type Ets2 gene produces a product of 500 bp. The Ets2
A72 generates a
600-bp product. The large Ets2
A72-Neo allele does not amplify under
these conditions. Lanes 1, 2, and 4 show products generated by the
excision of the ﬂoxed Neo. (E) Ets2
A72 protein turns over at the same
rate as does wild-type Ets2. A 7-day exposure of a sodium dodecyl
sulfate-acrylamide gel used to separate [
35S]methionine-labeled pro-
teins immunoprecipitated from wild-type or Ets2
A72/A72 embryo ﬁbro-
blasts is shown. Cells were labeled for 20 min and then incubated for
the indicated time in medium containing normal levels of nonradio-
active methionine. (F) Signal intensities were determined by NIH
Image software, normalized, and plotted as a function of time of chase.
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db1/db1 embryos. Without
prior knowledge of the complete rescue of Ets2
db1/db1 embryos
by tetraploid extraembryonic tissues (59), the retarded devel-
opment of the Ets2
A72/db1 embryos might be mistaken for an
embryonic growth defect. However, the rescue of Ets2
db1/db1
embryos has demonstrated that Ets2 is largely dispensable for
embryonic development. Because tetraploid embryo cells are
capable of colonizing and complementing both trophoblastic
and extraembryonic endoderm deﬁciencies (14), it remains to
be determined if the yolk sac abnormalities of the Ets2
A72/db1
embryos reﬂect an additional speciﬁc extraembryonic function
for Ets2. However, the later death of Ets2
db1/A72 embryos im-
plies a rank order of Ets2 alleles: Ets2
/  Ets2
A72/ 
Ets2
db1/  Ets2
A72/A72  Ets2
A72/db1  Ets2
db1/db1.
Adult Ets2
A72/A72 mice appeared normal with respect to
fertility and longevity. They also did not develop the hair ab-
normalities found in rescued Ets2
db1/db1 mice. Histological
analysis of 50 organs of three Ets2
A72/A72 adults did not reveal
abnormalities except for a single lung adenoma, which is com-
monly found in FVB/N mice (data not shown). Mammary
gland development of Ets2
A72/A72 females was normal and not
distinguishable from that of wild-type or heterozygous females
(data not shown).
Restriction of PyMT and Neu mammary tumors by limited
Ets2 activity. To test the effect of the Ets2
A72 allele on mam-
mary tumors, we generated homozygous and heterozygous
Ets2
A72 females which also carried the MMTV-PyMT trans-
gene (25). At 90 days, mammary tumors arising in the fat pads
of Ets2
A72/A72 female mice were less than half the size of those
of control animals with one wild-type Ets2 allele (Table 2).
This restriction on the development of PyMT tumors in
Ets2
A72/A72 mice resembled the previous observation of haplo-
FIG. 2. Haploinsufﬁciency of Ets2
A72. (A) Ets2
A72/ and Ets2
A72/db1 embryos with partially dissected yolk sacs at E10.5. Ets2
A72/db1 embryos are
smaller than Ets2
A72/ embryos, with no blood in the yolk sac. (B) Ets2
A72/db1 and Ets2
A72/ embryos at E11.5. Ets2
A72/db1 embryos are retarded
and small. (C and D) Hematoxylin-and-eosin-stained sections of placentas from E11.5 concepti. Maternal decidua (MD), giant cell layer (G),
spongiotrophoblast layer (ST), labyrinth layer (L), and yolk sac (YS) are indicated. Note that the spongiotrophoblast layer and labyrinth regions
are absent in panel D.
TABLE 1. Embryonic lethality of Ets2
A72/db1
Age
No. of Ets2
A72/A72  Ets2
db1/ mice
Ets2
A72/ Ets2
A72/db1 Resorption Total
E8.5 7 8 0 15
E10.5 6 11 1 18
E11.5 6 4 5 15
E12.5 11 0 12 23
Adult 33 0 33
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db1/;PyMT tumors (38). However, the pre-
vious experiment was performed on a mixed, outbred genetic
background. On an FVB/N background, the degree of restric-
tion by Ets2
A72/A72 was greater than that of Ets2
db1/ (data not
shown). However, the cellular composition and organization of
tumors arising in different Ets2 genotypes were very similar
and characteristic for these tumors (data not shown) (25).
PyMT signals through both Shc and PI3K pathways. Muta-
tion of PyMT tyrosines 315 and 322 results in defective acti-
vation of phosphatidylinositol 3-kinase (PI3K) by PyMT but
retention of signaling through the Shc adapter proteins and Src
(11, 56). Transgenic expression of a mutant form of PyMT
(PyMT
Y315,322F) results in highly apoptotic, cystic tumors, the
phenotype of which can be complemented by forced expression
of Akt, a downstream effector of PI3K (29, 56). As Ets2 might
be expected to act primarily downstream of Shc and the Ras
pathway, the degree of mammary tumor restriction by limited
Ets2 activity might be expected to be even greater in tumors
arising from PyMT
Y315,322F. The Ets2
A72 allele was combined
with the MMTV-PyMT
Y315,322F transgene. As expected, tu-
mor development was severely restricted in PyMT
Y315,322F;
Ets2
A72/A72 mice compared to PyMT
Y315,322F mice containing
wild-type Ets2 or only one Ets
A72 allele (Table 2). At 133 days,
only 30% of bigenic PyMT
Y315,322F;Ets2
A72/A72 mice developed
tumors (
2 analysis, P  0.0001). In addition, fewer tumors
were found in those mice that did develop tumors. Thus, lim-
ited Ets2 activity restricted the formation of PyMT tumors with
deﬁcient PI3K signaling.
The PyMT oncogene utilizes the same signal transduction
pathways as the Neu EGFR family member implicated in hu-
man breast cancer. To determine if Ets2 is also important in
Neu tumor development, we evaluated the effect of Ets2 on
tumor appearance in the MMTV-NeuNDL1-2 mice (Fig. 3A).
The MMTV-NeuNDL1-2 line expresses a form of Neu which
is activated by a deletion in the extracellular domain (48).
Tumor appearance was delayed in animals heterozygous for
the Ets2
db1 allele. However, restricting Ets2 activity did not
alter the penetrance of tumor formation that occurred in ap-
proximately 60% of the NeuNDL1-2 animals. Because of the
long latency and incomplete penetrance of the NeuNDL1-2
model, the impact of Ets2
A72 was evaluated further in the
MMTV-NeuYD mouse model (12). In this model signaling by
Neu is restricted by mutation of four of ﬁve tyrosines impli-
cated in signaling. A single remaining Shc binding site (ty-
rosine-1222) is sufﬁcient for tumor formation in all transgenic
females within about 20 weeks. MMTV-NeuYD females de-
veloped fewer and smaller tumors at an age of 20 weeks in
combination with Ets2
A72
(Fig. 3B and C). These results show
that activation of Ets2 through Thr-72 supports the develop-
ment of mammary tumors caused by oncogenic Neu-Erbb2.
The restriction of mammary tumors by limiting Ets2 activity is
not conﬁned only to tumors arising as the consequence of
PyMT expression and implies a similar function downstream of
FIG. 3. An Ets2 restriction of Neu mammary tumors. (A) Female
NeuNDL1-2 animals with the indicated Ets2 genotype were examined
for tumors three times weekly by palpation. (B and C) Six female
NeuYD mice either heterozygous (A) or homozygous (AA) for
Ets2
A72 were sacriﬁced at 20 weeks of age. The average weight (grams)
of the largest tumor of each animals is shown in panel B, and the
average number of tumors per mouse is shown in panel C. Error bars
indicate standard deviations. Two-tailed t test, P 	 0.034 for panel B
and 0.027 for panel C.
TABLE 2. Ets2
A72/A72 restriction of mammary tumors
Mouse group and characteristic Ets2
A72/A72 Ets2
A72/ Ets2
/
MMTV-PyMT at 90 days
No. of animals 6 12
Avg tumor wt (g) 0.62 1.6
SE 0.12 0.2
MMTV-PyMT
Y315,322F at 133 days
No. of animals 10 10 6
No. hyperplasia positive 10 10 6
No. of tumor-bearing mice
a 31 0 6
No. of tumors/tumor-bearing mouse 1.3 3.1 3.3
a Masses with diameters of 3 mm or greater were counted as tumors.
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Neu (13).
Ets2 acts downstream of VEGF. To test whether Ets2 reg-
ulates mammary tumors by an angiogenic mechanism, we uti-
lized transgenic mice which overexpress mouse VEGF164 in
mammary epithelial cells. The MMTV-VEGF-25 (VEGF-25)
line expresses approximately 25-fold-higher VEGF levels in
virgin mammary gland without altering mammary gland devel-
opment. However, tumor formation in NeuYD;VEGF-25 big-
enic animals was accelerated and was associated with greatly
increased vascularity of hyperplastic and tumor tissues (40a).
The Ets2
A72 gene was combined with the NeuYD and
VEGF-25 transgenes to evaluate tumor appearance. Ets2
A72/
A72 restricted the time of appearance of NeuYD tumors as
expected from the measurements of tumor number and size at
a single time point (Fig. 3B and C and 4A; log rank test, P 
0.004). The average time of tumor appearance was delayed 15
days in Ets2
A72/A72;NeuYD bigenic females. However, once the
tumors appeared, the growth rates of the two types of tumors
were similar (Fig. 4B and D; note similar tumor volumes at 15
days for both genotypes) for the ﬁrst 15 days.
If the Ets2 restriction of mammary tumors was due to a
function of Ets2 in regulating VEGF production, transgenic
VEGF expression might be expected to bypass an Ets2-sensi-
tive restriction. NeuYD tumors are restricted by angiogenesis
because transgenic expression of VEGF in the mammary epi-
thelium dramatically accelerates tumor formation coincident
with increased vascularization (40a) (Fig. 4A). However,
Ets2
A72/A72;NeuYD;VEGF-25 trigenic females developed tu-
mors more slowly (63 days) than did control Ets2
/;NeuYD;
VEGF-25 animals (Fig. 4A) (log rank test, P  0.008). In
addition, the growth of NeuYD;VEGF tumors was dramati-
cally diminished by limited Ets2 activity (Fig. 4C and E). How-
ever, the CD31-positive blood vessel density of Ets2-restricted
NeuYD;VEGF-25 tumors was not distinguishable from that of
control NeuYD;VEGF-25 tumors (data not shown). Further-
more, the Ets2
A72/A72 genotype did not have lower levels of
endothelial markers CD31, Flk-1, and VE-cadherin and T-
cadherin RNAs in these tumors, although all of the endothelial
markers were elevated in comparison to NeuYD tumor with-
out transgenic VEGF (data not shown) (40a). Thus, limiting
Ets2 activity restricts the appearance of both NeuYD tumors
(Fig. 4A; log rank test, P  0.004) and highly vascularized,
NeuYD;VEGF-25 tumors. Ets2
A72/A72 did not restrict the in-
creased vascularity caused by forced VEGF expression but still
restricted tumor appearance and growth. Western blots of
NeuYD;VEGF-25 tumors with differing Ets2 genotypes re-
vealed similar levels of Neu, Akt, and Grb2 proteins (data not
shown). Thus, the Ets2 restriction on VEGF-accelerated tu-
mors was not due to modulation of Neu expression or the
parallel stimulation of the Akt signaling pathway.
Increased p21
Cip1 in Ets2-restricted tumors. Expression of
several putative Ets2 target genes whose products could inﬂu-
ence tumor growth was assayed in the NeuYD;VEGF tumors
containing either wild-type Ets2 or Ets2
A72. These target genes
included cyclin D1 and Bcl-xL, both reported to be Ets2 re-
sponsive (1, 46); p21
Cip1, a reported target of the E1AF Ets
factor (21); and VEGF, whose expression in human breast
tumors has been correlated with Ets1 expression levels (50).
Figure 5 shows the results of real-time PCR quantitation of the
relative gene expression. While there was not a signiﬁcant
effect of the tumor Ets2 genotype on the expression of CycD1,
Bcl-xL, or endogenous VEGF, there was a 3.6-fold-higher level
of p21
Cip1 expression in the Ets2
A72/A72 tumors, which was
highly signiﬁcant (P 	 0.008). The increased p21
Cip1 expres-
FIG. 4. Ets2-dependent restriction of VEGF-25-accelerated
NeuYD tumor appearance. A comparison of the time of tumor detec-
tion in NeuYD female mice (Ets2-wt, squares) and NeuYD female
mice homozygous for Ets2
A72 (Ets2-AA, triangles) with bigenic
NeuYD;VEGF-25 female mice (VEGF Ets2-wt, inverted triangles)
or NeuYD;VEGF-25 mice homozygous for Ets2
A72 (VEGF Ets2-
AA, diamonds, broken line) is shown as a function of age. The aver-
ages and standard deviations of the time of ﬁrst detection are indi-
cated. Data from NeuYD animals and bigenic NeuYD;VEGF-25
animals have been submitted for publication elsewhere (40a) and are
presented here for comparison to the Ets2
A72/A72;VEGF-25 animals.
Log rank tests of survival plots indicated a statistically signiﬁcant dif-
ference between Ets2
/;NeuYD;VEGF-25 and Ets2
A72/A72;NeuYD;
VEGF-25 tumor appearance (P  0.03) and between Ets2
/;NeuYD
and Ets2
A72/A72;NeuYD tumor appearance (P  0.025). (B to E) Tu-
mor growth. Tumor size was measured with calipers, and the volume
was estimated (length  weight
2/2). Average tumor volumes are plot-
ted as a function of elapsed time after ﬁrst detection. Error bars
indicate the standard deviations. Linear curve ﬁt equations with cor-
relation coefﬁcients are shown for ease of comparison of growth rates.
Linear functions ﬁt all sets of data better than exponential curve ﬁt
except for panel B.
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limited tumors.
A stromal function for Ets2 in mammary tumors. Ets2 may
inﬂuence tumors in either epithelial or stromal supporting
cells. The stromal contribution of the Ets2-sensitive restriction
of PyMT
Y315,322F tumors was tested by tumor transplantation.
A well-characterized, serially transplantable tumor line from a
PyMT
Y315,322F tumor (PyMT
Y315,322F-DB7) (8, 56) was surgi-
cally inoculated bilaterally into mammary fat pads of adult
female Ets2
db1/ and Ets2
/ FVB/N strain mice. After 8 or 9
days, the fat pads were excised and the tumor size was mea-
sured. Figure 6A and B shows average examples of tumor
growth in the two Ets2 genotypes. All 34 transplants (20 in
Ets2
/ mice and 14 in Ets2
db1/ mice) resulted in tumors. No
correlation was found between tumor size and age or weight of
the hosts (data not shown). Tumors that arose in wild-type
animals were frequently larger than those in Ets2
db1/ mice
(Table 3; Fig. 7A). The average tumor arising in Ets2
db1/ mice
was only 52% of the volume of those in wild-type animals. The
difference between the two populations was statistically signif-
icant (Student t test, P 	 0.02).
A second trial was performed on eight animals of each
genotype in which the animals were all sacriﬁced at 9 days
(Table 3; Fig. 7B). In order to test the importance of the
mammary gland environment, six wild-type animals and four
Ets2
db1/ animals of the second transplant series also received
bilateral subcutaneous transplants. Only one mammary trans-
plant of each series failed to generate a tumor. Both the vol-
umes and variability of the mammary tumors were very similar
to those in the ﬁrst trial. The average tumor volume of
Ets2
db1/ mice was only 47.5% of that for Ets2
/ animals (P
	 0.008). Combined, the average volume of PyMT
Y315,322F
tumors arising in Ets2
db1/ mice was 50% of that of tumors
growing in animals with two wild-type Ets2 alleles (P 	
0.0004). The volume of the lymph node was not signiﬁcantly
different between genotypes.
To determine if activation of Ets2 through Thr-72 phosphor-
ylation is involved in the stromal support of transplanted tu-
mors, we performed the transplant experiment in Ets2
A72/A72
and Ets2
A72/ mice. We found that Ets2
A72/A72 hosts had an
average tumor volume 54% smaller than that of Ets2
A72/ mice
(P 	 0.04) (Table 4; Fig. 7C). Previously, on the basis of the
duration of embryonic development, we deduced a rank order
of the Ets2
db1 and Ets2
A72 alleles. Transplanted tumor size in
all trials decreased with decreasing Ets2 activity of the host
(Fig. 7D).
FIG. 5. Increased p21
Cip1 expression in Ets2-restricted bigenic tu-
mors. Expression of the indicated genes in NeuYD;VEGF tumors
containing either wild-type Ets2 or Ets2
A72/A72 was analyzed by quan-
titative reverse transcription-PCR. The cDNA levels for each sample
were normalized to Cph (Ppia) expression. The percent expression
shown for each gene is relative to the level of the average expression
of the same gene in the wild-type Ets2 tumors. Results shown are the
averages and standard deviations from duplicate experiments from at
least two different tumors of each genotype.
FIG. 6. Transplanted PyMT
Y315,322F-DB7 tumors are smaller in
Ets2
A72/A72 hosts and are associated with macrophage inﬁltration. (A,
C, and E) Ets2
A72/ hosts; (B, D, and F) Ets
A72/A72 hosts. (A and B)
Images of whole mounted mammary glands 9 days after tumor trans-
plantation. LN, lymph node; T, tumor. (C and D) Hematoxylin-and-
eosin-stained section of typical transplanted tumors. (E and F) Rep-
resentative tumor ﬁelds stained with F4/80 antibody in brown.
TABLE 3. Ets2 dependence of transplanted PyMT
Y315,322F-DB7
tumor size in Ets2
/ and Ets2
db1/ mice
Tumor type
Ets2
/ Ets2
db1/
Size (mm
3)
a n Size (mm
3)
a nP
b
Mammary pad (expt 1) 28.4 
 4.9 14 14.8 
 2.8 20 0.021
Mammary pad (expt 2) 32.0 
 45.2 15 15.2 
 2.4 15 0.008
Combined 29.9 
 3.5 29 15.0 
 3.5 37 0.0004
Subcutaneous 4.8 
 0.9 9 5.3 
 0.9 7 0.67
Lymph node 9.7 
 0.9 16 10.0 
 0.8 16 0.85
a Values are means 
 standard errors of the means.
b t test, two sample, assuming unequal variance. The difference between means
of the compared genotypes is not signiﬁcantly different for subcutaneous trans-
plants or for lymph nodes.
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Subcutaneous transplants of PyMT
Y315,322F-DB7 tumors grew
signiﬁcantly slower than did identically sized transplants placed
in the mammary fat pad (Table 3). The Ets2 genotype had no
signiﬁcant impact upon subcutaneous tumor growth after 9
days. This result is consistent with previous observations that
mammary tumor growth can be profoundly inﬂuenced by the
site of implantation (37). The Ets2-sensitive restriction on
mammary tumor growth is site speciﬁc and may involve a
stimulatory effect of the mammary stroma.
MMP-9 and factor VIII expression in transplanted tumors
depends on Ets2. Histological analysis of transplants into
Ets2
A72/A72 and Ets2
A72/ mice revealed that transplanted
PyMT
Y315,322F tumors resembled those previously described
(Fig. 6C and D) (8). Tumors were poorly differentiated carci-
nomas with a solid growth pattern. Mitotic cells were visible, as
were areas of necrosis. Tumors had a signiﬁcant host inﬂam-
matory reaction to the transplants (Fig. 6C and D). Inﬂamma-
tory cells and ﬁbroblastic proliferation were evident in the
mammary fat pads of all genotypes. Antibody staining of mac-
rophages with the F4/80 antibody revealed signiﬁcant macro-
phage presence within the tumor and in the tumor periphery
(Fig. 6E and F). However, quantitation of total F4/80 staining
did not reveal a signiﬁcant difference between Ets2 genotypes
(data not shown).
While the total inﬁltration of the transplanted tumors by
macrophages was not distinguishable by F4/80 staining, a sub-
set of cells that expressed elevated MMP-9 concentrated near
the tumor-host interface (Fig. 8A and B). More MMP-9-pos-
itive cells were found in Ets2
A72/ hosts than in Ets2
A72/A72
hosts (Fig. 8A, B, and G). These MMP-9-positive cells may
FIG. 7. PyMT
Y315,322F tumor size depends on the Ets2 genotype of
the host. Tumors were measured in digital images of whole-mount
mammary glands prepared 9 days after transplant of 1-mm
3 pieces of
the PyMT
Y315,322F-DB7 serially transplanted tumor line. (A and B)
Individual values of two replicate experiments using Ets2
/ and
Ets2
db1/ female hosts. (C) Results of transplantation into Ets2
A72/
and Ets2
A72/A72 hosts. (D) Average sizes and variation in different Ets2
genotype hosts.
FIG. 8. MMP-9 and factor VIII-reactive vasculature is Ets2 depen-
dent. (A and B) Representative ﬁelds of transplanted PyMT
Y315,322F-
DB7 tumor sections stained with MMP-9 antibody and hematoxylin.
The Ets2 genotype of the host is indicated. Arrows indicate represen-
tative positive reactive cells near the tumor-stromal interface. (C to F)
Immunohistochemical detection of vessels expressing factor VIII-re-
lated antigen. (C and D) Areas at the interface between the tumor and
stroma. (E and F) Representative ﬁelds within the tumor. Black arrows
indicate representative positive areas. Red arrows in panel F show
putative vessels not stained with factor VIII antibody. The bar in panel
F represents 100 m and is applicable to panels C to F. (G) The
numbers of MMP-9-positive cells were counted. Each value represents
the average of one tumor transplant section. The averages and stan-
dard errors are shown. (H) Factor VIII-positive vessel density was
determined by counting independent ﬁelds away from the tumor edge.
The averages and standard deviations are shown.
TABLE 4. Ets2 dependence of transplanted PyMT
Y315,322F-DB7
tumor size in Ets2
A72/ and Ets2
A72/A72 mice
Tumor type
Ets2
A72/ Ets2
A72/A72
Size (mm
3)
a n Size (mm
3)
a nP
b
Mammary pad 23.5 
 4.9 12 10.9 
 3.0 8 0.043
Lymph node 7.7 
 0.7 12 7.3 
 1.0 8 0.73
a Values are means 
 standard errors of the means.
b t test, two sample, assuming unequal variance. The difference between means
of the compared genotypes is not signiﬁcantly different for lymph nodes.
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or reactive ﬁbroblasts. As stromal expression of MMP-9 has
been implicated in making VEGF available during the angio-
genic switch of transgenic pancreatic cancer, we evaluated the
vasculature of the transplanted tumors by staining tumor sec-
tions with antibody to the endothelial marker factor VIII-
related antigen. Neither CD31 nor Flk-1 antibody reactions
were compatible with the preparation of these specimens. Ma-
ture vessels within the fat pads and at the tumor-stromal in-
terface of the tumors of both Ets2 genotypes were clearly
reactive with factor VIII antibody (Fig. 8C and D). However,
reactivity was greatly reduced within the body of the tumors of
Ets2
A72/A72 hosts (Fig. 8E and F) in spite of typical vessel-like
structures and the general absence of necrotic areas. Quanti-
tation of factor VIII antibody-reactive vessels within the body
of the tumors revealed a greater-than-threefold difference be-
tween Ets2
A72 homozygous and heterozygous hosts (Fig. 8H).
These results suggest a difference in vascular density or mat-
uration.
Ets2 regulates macrophage MMP-9 and MMP-3. The stro-
mal action of Ets2 and the invasion of transplanted tumors by
macrophages stimulated consideration of Ets2-dependent
gene expression in isolated macrophages. Macrophages were
isolated from bone marrow and activated by exposure to either
CSF-1 alone or the combination of IFN- and LPS. Ets2
A72/A72
macrophages contained dramatically lower levels of MMP-9
and MMP-3 RNAs than did controls after stimulation with
either condition (Fig. 9). However, Ets2 and Bcl-xL RNA
levels did not differ between Ets2 genotypes (Fig. 9). VEGF
RNA levels were lower in Ets2
A72/A72 macrophages stimulated
with CSF-1 but did not differ signiﬁcantly after activation with
LPS and IFN- (Fig. 9). These results show that the induction
of MMP-9 and MMP-3 expression is highly dependent on the
kinase activation of Ets2.
DISCUSSION
Ets2 activity is modulated by phosphorylation of Thr-72 in
vivo. The developmental defects caused by Ets2
db1/db1 and
Ets2
A72/db1 but not Ets2
db1/ or Ets2
A72/A72 provided a basis for
deducing the rank order of the Ets2 alleles: Ets2
/ 
Ets2
A72/  Ets2
db1/  Ets2
A72/A72  Ets2
A72/db1  Ets2
db1/db1.
As the A72 targeted mutation does not alter the expression of
Ets2
A72 RNA or the rapid turnover of Ets2
A72 protein, the
decreased Ets2 activity of Ets2
A72 is due to the absence of the
activating phosphorylation site. This conﬁrms in vivo the im-
portance of the Thr-72 residue of Ets2 as deduced in cell
culture transfection analysis (60) but also demonstrates that
the basal activity of Ets2 is functionally important. The devel-
opmental deﬁciencies caused by Ets2
A72/db1 and Ets2
db1/db1 are
due to trophoblast malfunction because tetraploid embryo ag-
gregation can rescue Ets2
db1/db1 embryo development (59).
The basal activity of the Ets2
A72 allele permits development to
proceed 3 days longer than Ets2
db1/db1 to E11.5. The absence of
embryonic blood cells in the Ets2
A72/db1 placenta reﬂects the
absence of the labyrinth layer due to an apparent failure of
chorioallantoic fusion. This could be considered a vascular
defect as the allantois is the source of the embryonic blood
vessels which normally interdigitate with the maternal circula-
tion in the placenta. However, the failure to form the labyrinth
region may be secondary to a proliferation defect of tropho-
blast cells. A deﬁciency of trophoblast cell growth in response
to factors such as FGF is consistent with the formation of giant
cells, which form in the absence of continued FGF stimulation
(52), and the absence of spongiotrophoblast and labyrinth lay-
ers.
Limited Ets2 restricts PyMT and Neu mammary tumors.
Haploinsufﬁciency of Ets2 restricts the development of PyMT
(38) and NeuNDL1-2 mammary tumors. The similar restric-
tion of PyMT, PyMT
Y315,322F, and NeuYD tumors by
Ets2
A72/A72 indicates that kinase activation of Ets2 through the
Thr-72 residue is important in the development of these mam-
mary tumors. One trivial explanation for the Ets2 restriction of
tumor development in these models might be a direct or indi-
rect Ets2 dependence of the MMTV promoter. There are four
observations that make this unlikely. First, PyMT
Y315,322F
RNA and Neu protein levels were similar in Ets2
A72/ and
Ets2
A72/A72 tumors and matched hyperplastic tissues. Second,
FIG. 9. Ets2 regulates MMP-3 and MMP-9 in macrophages. The
indicated RNAs derived from BMMs of Ets2
/ and Ets2
A72/A72 ani-
mals were measured by quantitative PCR. (A) Seven-day primary
macrophage cultures were treated with CSF-1; (B) combination of LPS
and IFN-. Values represent the averages of three different cell iso-
lates normalized to Cph expression. Target genes were assayed in
triplicate for each condition. Error bars represent standard deviations
of the averages of three samples.
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Ets2
A72 heterozygous and homozygous hosts. This suggests
that circulating levels of tumor growth factors including hor-
mones are likely similar in the two Ets2 genotypes. This con-
clusion is further reinforced by the normal hormone-depen-
dent development of the mammary epithelium in Ets2
A72/A72
females. Finally, transient-transfection analysis of MMTV pro-
moter constructions did not reveal signiﬁcant activation by
Ets2 (data not shown).
NeuNDL and NeuYD both activate Shc-dependent signal-
ing that leads to Ras and downstream kinase activation. Both
also activate the PI3K pathway by increasing Erbb3 protein
levels and downstream signaling targets including Akt. While
PyMT activates both Shc and PI3K pathways directly,
PyMT
Y315,322F requires a secondary event in order to progress
to a tumor. EGFR signaling complements the defective PI3K
signaling impaired by the Y315,322F mutations (56). Ets2 has
been implicated in mediating EGFR signaling because Ets2-
deﬁcient mice, rescued from early placental insufﬁciency, have
the same hair phenotype as the hypomorphic EGFR mutation
waved-2 (34), and in cultured ﬁbroblasts, Ets2 mediates EGF
transcriptional activation of MMP-3 (59). While it is clear that
Ets2 can mediate the downstream signaling of activated Neu
and EGFR, identiﬁcation of the speciﬁc target cell(s) respon-
sible for restricting mammary tumors is essential to under-
standing the molecular role of Ets2.
Ets2-dependent, stromal support of PyMT
Y315,322F tumors.
Ets2 deﬁciency in the stroma of the mammary fat pad restricts
tumor growth. This Ets2 stromal restriction is speciﬁct ot h e
mammary fat pad and was not manifest in subcutaneous posi-
tions. This restriction was revealed with the use of a transplant-
able tumor which generates lower vessel density and decreased
vessel tortuosity as a consequence of the mutation of the PI3K
binding sites of PyMT (8). This vascular deﬁciency of the
PyMT
Y315,322F-DB7 tumor cells may make them more depen-
dent upon a stromal source of angiogenic activity. The de-
creased factor VIII-positive vessel density and MMP-9-positive
cells associated with the Ets2
A72/A72 hosts are consistent with a
role of Ets2 in promoting host vascularization of the trans-
planted tumors. However, the absence of signiﬁcant necrosis in
transplanted Ets2
A72/A72 host tumors and the presence of fac-
tor VIII-negative vessels suggest that Ets2 might be more im-
portant to the function of endothelial cells.
Ets2 regulates MMP activity in macrophages. One of the
stromal cell types which is clearly impacted by Ets2
A72 is the
macrophage. Again, Ets2 deﬁciency appears more important
for the function than for the development of the target cells
because Ets2 is not necessary for the development of macro-
phages (26, 59) or their invasion of transplanted tumors. How-
ever, isolated macrophages had dramatic deﬁciencies in the
expression of both MMP-3 and MMP-9. MMP-3 has been
implicated previously in mouse mammary tumorigenesis and
the epithelial-to-mesenchymal transition of tumor cells (33,
51). Ets2-deﬁcient ﬁbroblasts are also defective in the induc-
tion of MMP-3 in response to either FGF or EGF (59).
MMP-9 is expressed by ﬁbroblasts, endothelial cells, and cells
of hematopoietic origin, but generally not carcinoma cells (15).
Ets2-deﬁcient trophoblast cells express little MMP-9 (59). Ets
transcription factors have been implicated in the EGF and Ras
regulation of MMP-9 (24, 55). The MMP-9-positive cells in our
tumor transplantation studies may correspond to a subpopu-
lation of macrophages, eosinophils, neutrophils, or reactive
ﬁbroblasts.
The phosphorylation of Ets2 has been implicated previously
in CSF-1 stimulation of macrophages (19, 49). This is consis-
tent with an important role of Ets2 in macrophage function,
although a speciﬁc role for Ets2 in the regulation of Bcl-xL,
another reported Ets2 target gene, was not found. Macro-
phages have a signiﬁcant effect on PyMT tumor progression
(32). However, the Ets2
A72/A72 restriction of PyMT tumors
appears more severe than that imposed by the deﬁciency of
macrophages in the Csf1
op/op mice. Thus, it is difﬁcult to as-
cribe all of the Ets2 restriction of mammary tumors to defec-
tive macrophage function.
Ets2 acts downstream of increased vascular density. Several
observations suggest a possible role for Ets2 in tumor angio-
genesis or endothelial function. First, VEGF RNA expression
was lower in Ets2
A72/A72 macrophages stimulated by CSF-1
(but not LPS and IFN-). Second, MMP-9 from inﬂammatory
cells has been previously implicated in making VEGF avail-
able for the progression of pancreatic cancer (5). Third, factor
VIII staining of the tumor blood vessels of transplanted
PyMT
Y315,322F mice distinguished Ets2-deﬁcient and normal
hosts. Finally, the developmental defect of Ets2
A72/db1 concepti
could be considered a vascular defect. Clearly, the transgenic
expression of VEGF164 overcomes a major restriction on
NeuYD tumor progression. However, Ets2 deﬁciency still re-
stricted VEGF-accelerated NeuYD tumors. Thus, Ets2 does
not limit tumors by regulating VEGF production by epithelial
cells. In addition, Ets2 does not likely regulate the mitogenic
response of endothelial cells to VEGF because Ets2
A72/A72;
NeuYD;VEGF-25 tumors had similar vessel density as those
with wild-type Ets2. Despite the similar tumor vessel density,
Ets2
A72/A72;NeuYD;VEGF-25 tumors grew signiﬁcantly more
slowly. This Ets2 dependence in tumor growth rate was re-
vealed only after accelerating the appearance and growth of
tumors by forced VEGF expression. The growth rates of both
PyMT and NeuYD tumors without transgenic VEGF are not
dependent on Ets2 genotype even though the time of tumor
onset is Ets2 sensitive (38). The elevated level of the cell cycle
progression inhibitor p21
Cip1 in Ets2
A72/A72;NeuYD;VEGF-25
tumors is consistent with the observed lower tumor growth
rate. However, p21
Cip1 is activated by strong stimulation of the
Ras-Raf signaling pathway (58) and is increased in response to
overexpression of the E1AF Ets transcription factor (21). The
elevated p21
Cip1 expression in the Ets2
A72/A72 tumors would
not be expected for an Ets2 loss-of-function mutation, unless
Ets2 acts by a negative mechanism (for example, see reference
2). Alternatively, elevated p21
Cip1 expression may reﬂect a
secondary effect of slower growth of the tumors caused by
limited Ets2 activity. The Ets2 restriction on VEGF-acceler-
ated tumors is likely distinct from the effects seen on vascularly
restricted PyMT and NeuYD tumors. The role of Ets2 in
endothelial cell function will be of great future interest.
Ets2 acts downstream of signaling pathways stimulated by
FGF and EGF (59), Erbb2 (23), Ras (22), Raf (36), and Erk
(19, 44). However, the functional importance of Ets2 in medi-
ating signaling through the Ras pathway in vivo is dependent
upon the speciﬁc cell type. The Ets2-dependent stromal sup-
port of tumors does not rule out additional effects of Ets2 in
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tors, PEA3, ESX/Elf-3, and Elf-1, have been implicated in
mammary tumors (4, 47, 53), normal mammary differentiation,
and Erbb2 regulation (43), respectively. Furthermore, in-
creased phosphorylation of Ets2 on Thr-72 is found in ovarian
cancer cell lines (41). Given the similarities in DNA-binding
speciﬁcities of multiple Ets members, selective inactivation of
individual Ets members in vivo provides the advantage of dis-
secting the speciﬁc role of individual Ets factors. Gene target-
ing has now implicated Ets2 in placenta development, hair
morphogenesis, and mammary tumor progression. Ets2 may
mediate growth factor signaling in all these cases.
Ets2 is necessary for embryonic development and for opti-
mal growth of tumors, but in both cases it may act primarily in
the support of the embryo or tumor rather than in the embryo
or tumor itself. It will be necessary to compare the relative
contributions of epithelial and endothelial cells, macrophages,
and other supporting cell types and appropriate growth factors
to understand fully the multiple molecular roles that Ets2 may
play during mammary tumorigenesis. The sensitivity of mam-
mary tumors to Ets2 activity stimulates consideration of
whether genetic variability of Ets2 activity may modify human
breast cancer disease.
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